NEW YORK (GenomeWeb News) — Qiagen last week acquired Genaco Biomedical Products for $22 million in cash, the company said today.
 
Qiagen purchased 100 percent of the company’s outstanding stock, and will pay out as much as $18 million in milestone payments from anticipated grants.  
 
Genaco is an early-stage company that uses a proprietary PCR-based multiplexing technology, called TEM-PCR, in its Templex molecular diagnostics, Qiagen said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.